Ger­man man­u­fac­tur­er hit with Form 483 for mul­ti­ple pro­duc­tion is­sues

Af­ter an in­spec­tion in Feb­ru­ary, the FDA has re­vealed con­cern­ing ob­ser­va­tions at a man­u­fac­tur­ing fa­cil­i­ty be­long­ing to Rentschler Bio­phar­ma in Ger­many.

The fa­cil­i­ty, a drug …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER